Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of HRS-4642 in combination with nab-paclitaxel and gemcitabine in advanced pancreatic cancer
CTR20254924Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4642 in pancreatic cancer (PC), sponsored by Hengrui Therapeutics. Started Jan 2026; status: active.
02
Drugs
HRS-4642
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20254924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254924.